• Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KOTRA
    • MSS
    • NIPA
    • SBA
  • Programs
    • SGSC Global Bootcamp 2021
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
    • KoreaTechDesk Monthly Pitch
  • Investment Opportunities
    • SGSC Demo Day
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • register
  • login
No Result
View All Result
No Result
View All Result
Home AI & Big Data

Korean startup Oncocross develops AI-platform that makes drug approval process quicker & less expensive

James Jung by James Jung
September 10, 2020
in AI & Big Data, Health & Bio, TIPS X beSUCCESS Global Project
0
Korean startup Oncocross develops AI-platform that makes drug approval process quicker & less expensive

Korean startup Oncocross making Ai-based platform for drug development & approval.

0
SHARES
509
VIEWS
Share on FacebookShare on Twitter

Drug development and approval have garnered much attention in times of COVID-19. Korean startup Oncocross is working towards the drug development area using AI-based biotechnology. The pharmaceutical company specializing in drug discovery and cancer drug development using its AI-based platforms.

The AI-based drug screening platform

The startup aims to increase the number of FDA approved drugs with lower cost in a shorter period by collaborating with big pharmaceutical companies, both global and Korea, in oncology, extended profile, IMD, and rescue drugs. For this, it has developed the two AI platform.

1) ONCO AI – An AI platform to screen optimal drug compound indications in preclinical or clinical stages and find the most suitable combination drugs to develop Incrementally Modified Drug (IMD) or orphan drugs, using proprietary human transcriptomic data (RNA expression), disease data, and drug data.  ONCO AI is used to accelerate the drug development process in a shorter time at a lower cost.

2) ONCOfind AI – An AI platform to screen and identify the most suitable biomarker for anti-cancer drug compound candidates using proprietary, standardized human transcriptomic data of multiple races and various cancer phenotype information. This platform can also identify the original anatomic site of primary cancer tumor for Carcinoma of Unknown Primary (CUP).

The startup’s service enables us to find an adequate indication of specific drugs and best partner drugs. ONCO AI platform allows patients to receive the best care and precision medicine, and pharmaceutical companies to increase the success rate of
drug development at low cost and less time.

Lower cost, Faster process

Oncocross’s approach to focus on drug candidates in the clinical stage or commercially available drugs can help pharmaceutical companies dramatically reduce the risk of both time and cost. As per an estimate by the company, the reduction can be up to 8 years and 95% of the cost.

The startup has already utilized its ONCO-AI initial screening process with some prominent pharma companies for various ailments like Jeil Pharma, ST Pharma, Korea Pharma, and Boehringer Ingelheim, a German multinational pharma. The startup believes that with time and cost saved, the ONCO-AI platform could prove to be very important for drug development and assessment in terms of global health security measures, especially in times of the COVID-19 pandemic.

Oncocross’ revenue model is based on license fees, co-development fees, and service fees, depending on the service and agreement. The Oncocross team, which consists of pharma, medicine, and finance experts, is headed by Yirang Kim, an experienced Medical Oncologist (Hematology). The startup wants to develop a domestic market as well as expand to the overseas market.

Oncocross is participating in the third edition of the “TIPS X beSUCCESS Korean startup showcase” to be held online on September 23-24, 2020. TIPS (Tech Incubator Program for startup Korea) is South Korean government-backed incubator, and beSUCCESS is Korea’s leading startup media company. The highly successful first two editions of the startup showcase were held in San Francisco and Palo Alto

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: Drug approvalFDAKorean StartupOncocrossOncologypharmaceuticalTIPS_GLOBAL_2020_3Q_TOP10
Previous Post

Is it a Genie or a Robot?: Korean startup’s ‘Genibot’ making coding, AI & STEAM fun for children

Next Post

Korean startup M2S uses VR content experience to develop a VR eye exam device

Next Post
Korean startup M2S uses VR content experience to develop a VR eye exam device

Korean startup M2S uses VR content experience to develop a VR eye exam device

0 0 votes
Article Rating
Subscribe
Login
Notify of
Please login to comment
0 Comments
Inline Feedbacks
View all comments
No Result
View All Result

FREE NEWSLETTER

PRODUCTS

Most Popular

  • DoubleMe that runs real-world metaverse platform ‘TwinWorld’ raises $25 million in funding 

    0 shares
    Share 0 Tweet 0
  • Top Korean Dating apps that can help you make new connections in South Korea

    12 shares
    Share 12 Tweet 0
  • FinTech startup Quantit & Privé Technologies award-winning robo-advisor RABIT helps crypto investments

    0 shares
    Share 0 Tweet 0
  • 10 K-Dramas to watch for some ‘money matters’

    0 shares
    Share 0 Tweet 0
  • Top 3 Websites where you watch Korean drama & movies

    12 shares
    Share 12 Tweet 0
  • AI media translation startup XL8AI attracts investment from Future Play 

    0 shares
    Share 0 Tweet 0
  • Korean startup Voithru’s global expansion platform JAMAKE allows YouTube influencers to truly own the world

    1 shares
    Share 0 Tweet 0
  • Korean startup Mars Auto set to launch self-driving trucks in 2023

    0 shares
    Share 0 Tweet 0
  • K-Pop music copyright trading platform Musicow attracts $79 million investment

    0 shares
    Share 0 Tweet 0
  • Korea’s leading Interior design platform ‘OHouse’  attracts $190 million in investment

    0 shares
    Share 0 Tweet 0
  • Facebook
  • Instagram
  • Twitter

Copyright © 2021 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact: [email protected] DMCA.com Protection Status

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KOTRA
    • MSS
    • NIPA
    • SBA
  • Programs
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
  • Investment Opportunities
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • Forums
  • register
  • login

Copyright © 2021 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact: [email protected] DMCA.com Protection Status

Posting....
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply

Insert/edit link

Enter the destination URL

Or link to existing content

    No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.